RBR‐42nd7q.

Study name	Medical record model oriented to problems with the use of medications in patients with heart failure admitted to the intensive care unit
Methods	Randomised controlled trial
Participants	Setting: Brazil Inclusion criteria: Over 18 years old Who have not been transferred from the ICU to other hospitals With an APACHE II score 20 With no current cancer diagnosis Absence of surgery in the last 6 months Who presented at least one PRM identified by the research pharmacists through the DAM medical record Exclusion criteria: Patients with data collection beginning after the first 48 hours of hospitalisation Patients with hospital stay less than 72 hours Patients who are admitted for palliative care Higher probability of early death (defined as death occurring between the 48th and 72nd hours of ICU admission) Patients diagnosed with suspected or confirmed brain death Patients aware that they refuse to participate in either group after randomisation Patients who refuse to participate in the study after recovering an adequate state of consciousness for decision‐making, when their entry is made by the authorisation of family members and/or guardian
Interventions	Intervention group: the Drug Therapy Intervention Group will receive care in which the problems related to medications will be diagnosed through the application of the diagnostics chart: a) adverse clinical findings and medications (DAM), followed by the establishment of conducts to solve drug‐related problems; (b) adjustment of drug treatment according to the previous step, which will be carried out by prescribers and nurses; (c) monitoring drug treatment on the evolution of drug‐related problems, achieving therapeutic goals and evaluating new drug‐related problems. A pharmaceutical conduct and therapeutic goals (care plan) will be recorded in the patient's medical record according to Classification for Drug related problems PCNE, V.8.01. Control group: the control group will receive the identification of drug‐related problems, however, instead of the subsequent intervention, the patients in this group will be subjected to the usual health care at the study sites. Care consists of evaluation of prescriptions by pharmacists, bedside visits and medication reconciliation.
Outcomes	Primary outcome: length of stay in the ICU (in days) Secondary outcomes: the Sequential Organ Failure Assessment (SOFA) and death scores
Starting date	Date first enrollment: 16 March 2018
Contact information	Tâmara Natasha Gonzaga de Andrade Santos Andrade Santos Phone: + 55‐79 99905‐1756, email: tamara_farmacia@hotmail.com
Notes	Trial ID: RBR‐42nd7q